PH12014502286B1 - Improving resistance to skeletal muscle fatigue - Google Patents

Improving resistance to skeletal muscle fatigue

Info

Publication number
PH12014502286B1
PH12014502286B1 PH12014502286A PH12014502286A PH12014502286B1 PH 12014502286 B1 PH12014502286 B1 PH 12014502286B1 PH 12014502286 A PH12014502286 A PH 12014502286A PH 12014502286 A PH12014502286 A PH 12014502286A PH 12014502286 B1 PH12014502286 B1 PH 12014502286B1
Authority
PH
Philippines
Prior art keywords
skeletal muscle
improving resistance
muscle fatigue
fatigue
improving
Prior art date
Application number
PH12014502286A
Other languages
English (en)
Other versions
PH12014502286A1 (en
Inventor
Fady Malik
Jeffrey R Jasper
Adam Kennedy
Darren Hwee
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of PH12014502286B1 publication Critical patent/PH12014502286B1/en
Publication of PH12014502286A1 publication Critical patent/PH12014502286A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12014502286A 2012-04-11 2014-10-10 Improving resistance to skeletal muscle fatigue PH12014502286A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US201261735809P 2012-12-11 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (2)

Publication Number Publication Date
PH12014502286B1 true PH12014502286B1 (en) 2014-12-15
PH12014502286A1 PH12014502286A1 (en) 2014-12-15

Family

ID=49328282

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502286A PH12014502286A1 (en) 2012-04-11 2014-10-10 Improving resistance to skeletal muscle fatigue

Country Status (15)

Country Link
US (2) US20150250784A1 (enExample)
EP (1) EP2836590A4 (enExample)
JP (2) JP6352244B2 (enExample)
KR (1) KR102163931B1 (enExample)
CN (2) CN111840294A (enExample)
AU (3) AU2013245917A1 (enExample)
BR (1) BR112014025251B1 (enExample)
CA (1) CA2869675C (enExample)
EA (1) EA032480B1 (enExample)
HK (1) HK1206389A1 (enExample)
IL (2) IL234886A (enExample)
MX (1) MX2014012179A (enExample)
PH (1) PH12014502286A1 (enExample)
SG (2) SG10201704166RA (enExample)
WO (1) WO2013155262A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
RS63018B1 (sr) * 2014-04-29 2022-04-29 Cytokinetics Inc Metode za smanjenje opadanja vitalnog kapaciteta
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2017002853A (es) 2014-09-09 2018-01-12 Astellas Pharma Inc Nueva composicion farmaceutica para la prevencion y/o el tratamiento de la incontinencia urinaria.
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CN109476645A (zh) 2016-07-14 2019-03-15 辉瑞大药厂 作为vanin-1酶抑制剂的新的嘧啶甲酰胺
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
BR112022000281A2 (pt) 2019-07-23 2022-02-22 Amorphical Ltd Carbonato de cálcio amorfo para aprimorar o desempenho atlético
AR124008A1 (es) 2020-11-06 2023-02-01 Cytokinetics Inc 1,4-diazepanonas bicíclicas y sus usos terapéuticos
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EA201001224A1 (ru) * 2008-02-04 2011-08-30 Цитокинетикс, Инкорпорейтед Химические соединения, композиции и способы их использования
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
MX354965B (es) * 2012-04-02 2018-03-27 Cytokinetics Inc Metodo para mejorar la funcion del diafragma.

Also Published As

Publication number Publication date
EA201491666A1 (ru) 2015-03-31
CN104395458A (zh) 2015-03-04
JP6352244B2 (ja) 2018-07-04
CN111840294A (zh) 2020-10-30
US20150250784A1 (en) 2015-09-10
KR20160046694A (ko) 2016-04-29
MX2014012179A (es) 2015-07-14
SG10201704166RA (en) 2017-06-29
EP2836590A4 (en) 2016-04-13
JP2015516392A (ja) 2015-06-11
WO2013155262A2 (en) 2013-10-17
BR112014025251B1 (pt) 2021-03-02
CA2869675C (en) 2022-06-14
HK1206389A1 (en) 2016-01-08
WO2013155262A3 (en) 2013-12-27
IL250473A0 (en) 2017-03-30
AU2018200930A1 (en) 2018-03-01
CA2869675A1 (en) 2013-10-17
KR102163931B1 (ko) 2020-10-12
JP6535727B2 (ja) 2019-06-26
JP2018048209A (ja) 2018-03-29
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
PH12014502286A1 (en) 2014-12-15
SG11201406359TA (en) 2014-11-27
AU2019268177A1 (en) 2019-12-12
US20190167676A1 (en) 2019-06-06
AU2013245917A1 (en) 2014-10-23
IL234886A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
AU2019268177A1 (en) Improving resistance to skeletal muscle fatigue
HK1206364A1 (en) Methods for improving diaphragm function
PH12014501108A1 (en) Anti-il-36r antibodies
PH12012501494A1 (en) Treatment of cardiac conditions
PH12014502698B1 (en) Improved antagonist antibodies against gdf-8 and uses therefor
MX2015008114A (es) Derivados de exendina-4.
PT2629610T (pt) Métodos e composições para prevenção e alívio de cãibras musculares e para recuperação de irritabilidade e fadiga neuromuscular após exercício
MX361862B (es) Composiciones y métodos que comprenden variante de enzima lipolítica.
MX2015002873A (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
HK1202244A1 (en) Prebiotic formulations and methods of use
IN2015DN03322A (enExample)
FI20116007A0 (fi) Serotoniinitason nostaminen ja diagnostisointi
NZ701463A (en) Anti-phytopathogenic composition
ZA201404537B (en) Method and composition for increasing the proportion of dietary ingredients that are resistant to degradation by ruminal microorganisms
BR112015012081A2 (pt) tratamento de café solúvel
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
PH12014502259A1 (en) Association of beta-glucans and arabinoxylans
WO2012035032A3 (en) Taste enhancement
NZ733721A (en) Methods for improving resistance to skeletal muscle fatigue
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201990302A1 (ru) Способы повышения устойчивости скелетных мышц к утомлению
MX2013012135A (es) Metodos y composiciones adecuadas para prevenir y tratar hiperleptinemia.
MX2019002801A (es) Uso de una composicion farmaceutica que comprende un anticuerpo anti-il-4r en el tratamiento de la dermatitis atopica.